Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
HONG KONG – Cadila Healthcare Ltd. (Zydus Cadila) has won approval for its saroglitazar to be used as the treatment of non-cirrhotic nonalcoholic steatohepatitis (NASH) in India. The green light from the Drug Controller General of India (DCGI) makes saroglitazar the first drug in the world approved for this indication.
PERTH, Australia – With the Brexit split now official, Australia’s Therapeutic Goods Administration is trying to figure out the impact to its life sciences industry and the new trade relationships that will take effect after the transition period ends.
HYDERABAD, India – India could play a key role in driving down the exorbitant cost of emerging cell and gene therapies, with a combination of comparatively cheap labor and efficient manufacturing, international experts said during the annual BioAsia conference.
HYDERABAD, India – Multinationals and domestic companies are stepping up research in India, including working to leverage the country’s digital and entrepreneurial capabilities, to boost India’s capabilities and market share in more innovative biologic drugs.
LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from WHO Director General Tedros Adhanom Ghebreyesus.
HONG KONG – South Korea’s venture capital investment in the biopharma and medical sector set a new record in 2019. According to Korea Venture Capital Association (KVCA), local VC firms invested ₩1.1 trillion (US$930 million) over a total of 299 bio and medical ventures last year, representing 25.8% of the total VC investment executed in 2019.